Enterovirus 2A<sub>pro</sub> Cleavage of the YTHDF m<sup>6</sup>A Readers Implicates YTHDF3 as a Mediator of Type I Interferon-Driven JAK/STAT Signaling

Jonathan P. Kastan,a,b Martine W. Tremblay,b Michael C. Brown,a Joseph D. Trimarco,c Elena Y. Dobrikova,a Mikhail I. Dobrikov,a Matthias Gromeiera

aDepartment of Neurosurgery, Duke University Medical Center, Durham, North Carolina, USA
bUniversity Program in Genetics and Genomics, Duke University Medical Center, Durham, North Carolina, USA
cMolecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA

ABSTRACT Enteroviruses (EV) deploy two proteases that mediate viral polyprotein cleavage and host cell manipulation. Here, we report that EV 2A proteases cleave all three members of the YTHDF protein family, cytosolic N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) "readers" that regulate target mRNA fate. YTHDF protein cleavage occurs very early during infection, before viral translation is detected or cytopathogenic effects are observed. Preemptive YTHDF protein depletion enhanced viral translation and replication but only in cells with restrained viral translation, signs of inefficient 2A protease activity, and protective innate host immune responses. This effect corresponded with repression of interferon (IFN)-stimulated gene (ISG) induction, while type I/III IFN production was not significantly altered. Moreover, YTHDF3 depletion impaired JAK/STAT signaling in cells treated with type I, but not type II, IFN. YTHDF3 depletion’s stimulatory effect on viral dynamics was dampened by JAK/STAT blockade and enhanced by type I IFN pretreatment of cells. We propose that EV 2A proteases cleave YTHDF proteins to antagonize ISG induction in infected cells.

IMPORTANCE It is believed that ~7,000 messenger RNAs (mRNAs) are subject to N<sup>6</sup>-methyladenosine modification. The biological significance of this remains mysterious. The YTHDF m<sup>6</sup>A readers are three related proteins with high affinity for m<sup>6</sup>A-modified mRNA, yet their biological functions remain obscure. We discovered that polio/enteroviruses elicit very early proteolysis of YTHDF1 to 3 in infected cells. Our research demonstrates that YTHDF3 acts as a positive regulator of antiviral JAK/STAT signaling in response to positive single-strand RNA virus infection, enabling type I interferon (IFN)-mediated gene regulatory programs to unfurl in infected cells. Our observation of viral degradation of the YTHDF proteins demonstrates that they are key response modifiers in the innate antiviral immune response.

KEYWORDS 2A protease, enterovirus, Jak/Stat signaling, poliovirus, YTHDF proteins, innate immunity, interferon stimulated gene, m<sup>6</sup>A modification, type I interferon, type III interferon

N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) modification of mRNAs influences diverse processes governing RNA metabolism, including splicing, nucleocytoplasmic transport, template stability, and translation (1–9). The YTHDF1 to 3, labeled "m<sup>6</sup>A readers" due to their affinity for m<sup>6</sup>A-modified RNA (10, 11), assume key roles in these processes that remain poorly understood.

Positive-sense single-strand (+ss) RNA viruses are a central focus for uncovering the biological significance of YTHDFs, because their genomes are m<sup>6</sup>A-modified (12, 13) and because m<sup>6</sup>A is implicated in controlling antiviral type I IFN (14, 15) and IFN-
stimulated gene (ISG) responses (2, 3). If YTHDFs are involved in orchestrating innate antiviral immunity, they may be targets of viral countermeasures.

ssRNA viruses deploy viral proteases for processing of their polyproteins. In some instances, these proteases also execute targeted cleavage of host cell proteins as part of the viral replication strategy (16). Enteroviruses (EV) encode two cysteine proteases; 3Cpro processes most polyprotein cleavages. Meanwhile, 2Apro mainly cleaves the polyprotein at the P1-P2 junction (17) but degrades host proteins with vital functions in translation (eukaryotic initiation factor [eIF] 4G1/2) and nucleocytoplasmic transport (nuclear pore complex components Nup153 and p62) (18, 19).

An unbiased screen for human host cell targets of 2Apro yielded a very small set of proteins containing the conserved consensus poliovirus (PV) 2Apro auto-proteolytic cleavage motif (LTTYG) (17). Among them were YTHDF1 and YTHDF3. Here, we show that YTHDF1, 2, and 3 are cleaved in EV-infected HeLa cells at a rate similar to that of eIF4G1, the emblematic host cell target for 2Apro (18). YTHDF3 depletion enhanced viral translation and replication exclusively in cell lines that mount robust, protective innate antiviral responses to infection. Functional studies with YTHDF3 depletion in EV-infected cells revealed elevated induction of IFN response factor 3 (IRF3) phosphorylation and IFN-β/λ1 mRNAs, while IFN-β/λ1 release was not significantly altered. However, IFN-stimulated gene (ISG) induction was diminished substantially. The stimulatory effects of YTHDF3 knockdown on EV dynamics were dampened by blockade of the JAK/STAT pathway and enhanced by IFN pretreatment in cells. Indeed, our findings implicate 2Apro-mediated YTHDF3 cleavage as a potential viral strategy to impair JAK/STAT signaling in infected host cells.

RESULTS

Enterovirus 2Apro mediates cleavage of YTHDF proteins. To establish a list of candidate host proteins that may be targeted by PV 2Apro for cleavage, we performed a proteome-wide BLAST search for the Leu-Thr-Thr-Tyr-Gly (LTTYG) pentamer, the conserved 2Apro-targeted sequence context at the cleavage site separating the P1 and P2 precursor polypeptides of PV (17). A 5-amino acid (aa) motif was chosen, as this is the consensus context reported to be critical for 2Apro substrate recognition (20). This approach yielded a list of only 10 putative 2Apro targets with an exact match for this pentamer (Fig. 1A). Notably, the list included YTHDF1 and 3, RNA-binding proteins with preference for methylated RNA (10, 11). YTHDF2 was not picked up in our screen, because it contains an LTSYG pentamer (Fig. 1B). Ser in position P2 of the 2Apro target sequence does not diminish proteolytic processing (20); therefore, YTHDF2 also is a plausible 2Apro target. Due to their implication in posttranscriptional regulation of viral genomic RNAs (21), in the life cycle of RNA viruses (13, 22), and in host innate antiviral immunity (15, 23), we decided to investigate YTHDF1 to 3 as putative 2Apro substrates and codeterminants of the EV-host cell relationship.

To elucidate the dynamics of YTHDF protein expression/cleavage during EV infection, we infected HeLa cells with an attenuated poliovirus (24) containing a heterologous internal ribosomal entry site (IRES) of human rhinovirus type 2 (PVSRIPO) (25) or a related EV, coxsackievirus B3 (CBV3; Fig. 1C). This revealed that YTHDF1, 2, and 3 are cleaved over the course of infection, with rapid loss of full-length protein and the appearance of an ~50- to 55-kD fragment corresponding to the predicted size of the C-terminal fragment produced by cleavage at LTTYG (Fig. S1). The earliest cleavage of YTHDF1 and 3 was observed at 3 to 4 hpi in PVSRIPO-infected cells, prior to detection of viral translation products, with comparable kinetics to those of the signature 2Apro-mediated cleavage of eIF4G1 (Fig. 1C). In contrast, earlier reported cleavages attributed to the poliovirus 3C protease, Ras-GAP SH3 domain-binding protein (G3BP) (26), and poly(A) binding protein (PABP) (27) did not occur before 5 hpi in PVSRIPO/CBV3 infected cells, an interval with rampant viral translation (Fig. 1C). To determine if 2Apro was sufficient for cleavage of YTHDF1 to 3, as suggested by the presence of the PV 2Apro autocatalytic cleavage motif (Fig. 1A and B), we transfected in vitro transcribed
RNA encoding wild type (WT) poliovirus 2Apro or the catalytically inactive 2Apro(C109A) (28) (Fig. 1D). WT 2Apro expression yielded YTHDF1 to 3 cleavage, while the catalytically inactive variant did not (Fig. 1D).

PV/CBV3 infection of HeLa cells produces profound cytotoxicity associated with generalized, indiscriminate proteolytic degradation of the host proteome at the peak of unfettered viral protein synthesis and the onset of morphologically evident cytopathogenic effects (CPE). Therefore, it is pivotal to distinguish early proteolytic events that occur prior to the onset of CPE, and that shape the virus-host relationship, from late, wholesale lytic degradation. To eliminate a potential role of organized cell death programs in the cleavage of YTHDF1 to 3 in EV-infected cells, we carried out infections in cells cotreated with escalating concentrations of Z-VAD-fmk, a pan-caspase inhibitor (Fig. 1E). This reduced cleavage of PARP, a caspase substrate, even at the lowest concentration tested but had no effect on YTHDF1 to 3 cleavage at any concentration (Fig. 1E).

Lastly, we transfected cells with constructs expressing WT myc-YTHDF3-Flag or a variant with the Tyr-Gly (Y\textsubscript{90}G) cleavage site mutated to Ala-Ala (Fig. 1F). These cells were then infected with PV/SRIPo, lysed at 8 hpi, and processed for Flag immunoprecipitation (Fig. 1F). This revealed the characteristic ∼54-kD cleavage fragment in cells expressing the WT YTHDF3 construct but not the variant with the A\textsubscript{9}A substitution of the 2Apro cleavage site. In aggregate, our findings indicate that YTHDF1 to 3 are

![FIG 1](enterovirus2aprom.png)
cleaved by EV 2Apro at predicted consensus 2Apro cleavage sites early during infection, prior to the onset of bulk viral translation and host CPE. This scenario suggests that viral cleavage of YTHDF1 to 3 may be a critical factor in the EV-host relationship.

**YTHDF3 antagonizes PVSRIPO replication and translation.** To decipher the physiologic significance of viral YTHDF1 to 3 cleavage for host-virus interactions, we focused on YTHDF3, as it was most rapidly cleaved during EV infection. Because innate antiviral immunity is a central area of interest for deciphering m6A and YTHDF biology, we employed a panel of four cell lines with diverse permissiveness for viral, m7G-cap-independent translation of PVSRIPO and, accordingly, distinct innate antiviral host responses to infection (Fig. 2A). PVSRIPO elicits robust type I/III IFN responses, orchestrated by host sensing of viral RNA signatures, engaging the pattern recognition receptor (PRR) melanoma differentiation associated protein 5 (MDA5) (29, 30). This is evident, as phosphorylation of STAT1 (Y701), downstream of the type I/III IFN receptors, was induced upon PVSRIPO infection (Fig. 2A).

HeLa (cervical carcinoma, human papillomavirus 18 infected) and SUM149 (breast cancer) cells permit rampant early viral translation and efficient eIF4G1 cleavage (substantial reduction of intact eIF4G1 prior to 6 hpi) and do not mount effective antiviral
host responses to PVSRIPO (multiplicity of infection [MOI] 10). This is evident by a failure to properly induce p-STAT1(Y701) upon PVSRIPO infection (Fig. 2A). SUM149 did not respond with p-STAT1(Y701) induction; delicate p-STAT1(Y701) immunoblot signal in PVSRIPO-infected HeLa cells occurred only at 8 hpi, at an interval with robust viral translation and after the onset of CPE (Fig. 2A). Accordingly, there was an inability to protect cells from rapid eIF4G1 cleavage (Fig. 2B), the early burst of viral translation (Fig. 2B), and early (12 hpi) virus-induced death (Fig. S2). Thus, infection of HeLa and SUM149 cells resulted in overt CPE by 12 hpi (Fig. S2). Preemptive YTHDF3 depletion in HeLa and SUM149 cells had no discernible effect on PVSRIPO translation or eIF4G1 cleavage (Fig. 2B and C). Thus, in cells that permit unimpeded early viral translation and 2Apro activity yielding efficient eIF4G1 and YTHDF protein cleavage, YTHDF3 depletion did not change the host-PVSRIPO relationship (Fig. 2B and C).

Compared to that in HeLa and SUM149 cells, PVSRIPO translation in A375 (melanoma) and T3M4 (pancreatic ductal adenocarcinoma) cells was delayed and eIF4G1 cleavage was inefficient (Fig. 2D and E). Indeed, PVSRIPO-infected A375 and T3M4 cells retained substantial amounts of intact eIF4G1 at 24 hpi, while HeLa and SUM149 cells were already lysed at that interval (Fig. 2B and C; Fig. S2). Accordingly, A375 and T3M4 cells responded with vigorous innate immune responses to PVSRIPO (MOI 10) infection, evident by abundant p-STAT1(Y701) induction (Fig. 2A). Corresponding with a protective host innate antiviral response delaying the early burst of viral translation and obstructing eIF4G1 cleavage, overt CPE was delayed/incomplete in A375 cells and absent in T3M4 cells (Fig. S2). A375 cells had no baseline p-STAT1(Y701) and responded with p-STAT1(Y701) induction only after PVSRIPO infection (Fig. 2A). In contrast, T3M4 exhibited baseline p-STAT1(Y701) signaling, indicating intrinsically active JAK/STAT1 signaling in the absence of virus challenge (Fig. 2A).

YTHDF3 depletion profoundly affected viral translation and eIF4G1 cleavage in PVSRIPO-infected (MOI 10) A375 and T3M4 cells (Fig. 2D and E). Furthermore, PVSRIPO propagation, which is surprisingly robust in the presence of an active, protective innate antiviral response (31), was enhanced by YTHDF3 depletion in accordance with the level of induction of viral translation (Fig. 2D to G). In T3M4 cells, YTHDF3 depletion propelled PVSRIPO propagation ~9-fold at 24 hpi (Fig. 2F). Divergent values at the 0 hpi interval in Fig. 2F were due to inherent variability of virus recovery from crude cell lysates in the assay; YTHDF3 depletion had no significant effect on virus attachment or entry (Fig. 2G). The stimulatory effects of YTHDF3 depletion on viral translation and eIF4G1 cleavage (Fig. 2D) were confirmed with a distinct siRNA probe and in A375 cells infected at a range of MOIs of 10, 1, and 0.1 (Fig. S3). We also assessed the effects of YTHDF3 and 2 knockdown in A375 cells infected with PVSRIPO at MOIs of 10, 1, and 0.1 (Fig. S4). Depletion of YTHDF1 or 2 had comparable stimulatory effects on viral translation and eIF4G1 cleavage to those of YTHDF3 knockdown in A375 cells (Fig. 2D; Fig. S3 and S4). Together, these observations point toward a role for YTHDF1 to 3 in shaping the PVSRIPO-host relationship through their influence on the innate antiviral defense.

YTHDF3 facilitates signaling downstream of IFN production induced by EV infection. To determine if YTHDF3 is a factor involved in the innate antiviral response, we depleted YTHDF3 in A375 and T3M4 cells prior to infection with PVSRIPO (MOI 10) or transfection with high molecular weight (HMW) poly(l:C) and examined activation of antiviral signaling (Fig. 3). It has been shown that transfection with HMW poly(l:C) mimics innate activation via Toll-like receptor 3 and MDA5 (30, 32). Our approach tested four stages of the innate response to PVSRIPO/poly(l:C) in A375 cells: (i) IRF3 (S396) phosphorylation, an immediate consequence of TBK1:IKKε activation after engaging MDA5 (Fig. 3A), (ii) induction of type I/III IFN mRNAs upon IRF3 activation (Fig. 3B), (iii) production and release of type I/III IFN (Fig. 3C), and (iv) induction of p-STAT1(Y701) and ISGs (STAT1, MDA5, IFIT1, ISG15, OAS1) downstream of the type I/III IFN receptors (Fig. 3A and D).

A375 cells responded to PVSRIPO infection with induction of IRF3(S396) phosphorylation as early as 8 hpi (Fig. 3A). This event was enhanced upon YTHDF3 depletion throughout the time course at 8, 24, and 30 hpi (Fig. 3A). A global loss of immunoblot
signal at 30 hpi in cells treated with YTHDF3 siRNA (also evident in Fig. 2D) is due to enhanced viral translation/propagation resulting in accentuated CPE upon YTHDF3 depletion. Elevated levels of IRF3 activation corresponded with significantly enhanced induction of type III (λ1) IFN transcripts at 30 hpi, while induction of type I (β) IFN mRNA was also increased, albeit insignificantly (Fig. 3B). Meanwhile, YTHDF3 depletion diminished PVSRIPO-induced IFN-β/λ1 release; however, this effect was not statistically significant (Fig. 3C). Opposite effects of YTHDF3 depletion on type I/III IFN template abundance versus those on type I/III IFN protein levels may be related to increased virus-induced cleavage of eIF4G and broad suppression of host protein synthesis that this event portends (Fig. 2D and E). This may impinge on type I/III IFN biosynthesis. Overall, these findings indicate that YTHDF3 is not involved in sensing viral RNA signatures or in the signaling pathway culminating in type I/III IFN release orchestrated by MDA5.

The principal effect of YTHDF3 depletion on the innate host response to PVSRIPO infection was dampened induction of ISGs (STAT1, MDA5, IFIT1, ISG15, OAS1) (Fig. 3A). This was also observed in YTHDF3-depleted cells transfected with poly(I:C) (Fig. 3D).
A375 cells did not respond with detectable IRF3(S396) phosphorylation to poly(I:C) transfection (Fig. 3D).

In T3M4 cells—which exhibit baseline IRF3(S396) phosphorylation and ISG expression in the absence of PVSRIPO infection/poly(I:C) transfection—the response to YTHDF3 depletion was broadly reduced p-STAT1(Y701) and ISG expression at baseline (0 hpi) and at 8 hpi (Fig. 3E). This effect was overcome by innate “super”-activation upon PVSRIPO (MOI 10) infection at 24 and 30 hpi, which elevated the innate host antiviral response beyond baseline levels (Fig. 3E). As with A375 cells, poly(I:C) transfection recapitulated the effects of YTHDF3 depletion on the ISG response induced by PVSRIPO in T3M4 cells (Fig. 3F).

Our findings indicate that YTHDF3 depletion stimulates PVSRIPO translation and replication through interfering with the innate host response at a node that occurs after type I/III IFN release. In A375 cells, YTHDF3 depletion inhibited ISG induction that was triggered by PVSRIPO infection or poly(I:C) transfection. In T3M4 cells, with active baseline STAT1 signaling, YTHDF3 depletion diminished innate activation at 0 to 8 hpi, during the critical early phase of PVSRIPO infection. The latter may explain the more robust stimulatory effect on viral translation upon YTHDF3 depletion in T3M4 cells compared to that in A375 cells (Fig. 2D and E).

YTHDF3 facilitates JAK/STAT1 signaling downstream of type I IFN. Our data suggest that YTHDF3 depletion affects the host cell response to PVSRIPO infection at a step between type I/III IFN release and p-STAT1(Y701) induction, which points to a defect in IFN-dependent JAK/STAT1 pathway activation. To test this, we examined the effect of YTHDF3 depletion on A375 cells treated with either (type I) IFN-α or (type II) IFN-γ, which signal to and converge on STAT1 through diverse receptor signaling modules (Fig. 4A to C). YTHDF3 depletion reduced p-STAT1(Y701) induction upon treatment with IFN-α in A375 (Fig. 4A) and HeLa cells (Fig. 4B) but not after treatment with IFN-γ (Fig. 4C).

Our data show that YTHDF3 positively regulates type I IFN-induced JAK/STAT1 activity. To confirm this, we depleted YTHDF3 in A375 cells, in the presence or absence of Ruxolitinib (Rux), a specific JAK1/2 inhibitor (Fig. 4D). If YTHDF3 influences the PVSRIPO-host innate immune relationship by facilitating JAK/STAT1 signaling, Rux should mitigate the effects of YTHDF3 depletion on PVSRIPO described in Fig. 2D. This was indeed the case, as Rux significantly dampened the stimulatory effect of YTHDF3 depletion on PVSRIPO translation (Fig. 4D).

To further test the role of the JAK/STAT pathway in mediating the stimulatory effect of YTHDF3 knockdown on PVSRIPO, we pretreated HeLa cells with IFN-α prior to infection and assessed the levels of viral translation upon YTHDF3 depletion (Fig. 4E). While YTHDF3 knockdown did not substantially alter viral translation in untreated HeLa cells (see also Fig. 2B), it significantly enhanced viral translation in IFN-α-pretreated HeLa cells. This corresponded with reduced levels of p-STAT1(Y701) and IFIT1 induction (Fig. 4E). Our findings suggested that YTHDF3 may play a role in regulating suppressor of cytokine signaling (SOCS) mRNA and protein expression, as the decay of mRNAs encoding these negative regulators of JAK/STAT signaling is regulated by m^6^A in T cells during murine development (33). However, in our system, transcripts encoding SOCS proteins or their functional homolog USP18 were not induced by YTHDF3 knockdown (Fig. S5A). Furthermore, SOCS1 and 3, which act specifically on type I-IFN-driven JAK/STAT1 signaling, remained unchanged at the protein level in YTHDF3-depleted cells before and during IFN-α2 treatment (Fig. S5B). Thus, the impact of YTHDF3 depletion on type I-IFN-driven JAK/STAT1 signaling occurs via a SOCS-independent mechanism.

**DISCUSSION**

Proteolytic targeting of the YTHDF proteins by EV 2A^pro^ is consistent with recent reports that the cellular RNA methylation machinery, in the context of +ssRNA virus infection, is antiviral in nature (12). While genomic RNAs of EVs (13) and other +ssRNA viruses (12) were reported to be methylated, we focused on YTHDF proteins in the
context of the host innate response to infection, as a large number of host cell transcripts (>7,000) are m6A-modified (11). Proteolytic degradation of YTHDF proteins in EV-infected cells occurs very early, prior to detectable viral translation, and before CPE manifests. Immediate early interference with YTHDF protein function implicates 2Apro-mediated cleavage as a viral ploy to oppose the antiviral host response, specifically induction of ISGs, in infected host cells. Indeed, preemptive YTHDF1, 2, or 3 depletion each enhanced viral translation and replication in PVSRIPO-infected cells that restrict early viral translation and eIF4G1 cleavage (A375, T3M4), resulting in inefficient viral 2Apro activity and eIF4G1 cleavage. Confirming this role for viral 2Apro-mediated YTHDF1 to 3 cleavage, YTHDF3 depletion failed to stimulate viral translation in cells that intrinsically permit efficient viral translation and 2Apro-driven proteolytic events (HeLa, SUM149).

Deciphering the effects of YTHDF3 depletion on the innate host response to PVSRIPO infection indicated that the YTHDF proteins act at a step after IFN-β/IFN-α release, implicating YTHDF3 as a mediator of JAK/STAT1 signaling. The classic EV-host cell interference event, 2Apro activities associated with cleavage of eIF4G1/2, contributes to blocking host m7G-cap-dependent translation (18). A 2Apro-driven viral program to subvert host defenses in infected host cells may encompass concerted cleavages of YTHDF proteins and of eIF4G1/2, preventing ISG induction. A role for YTHDF proteins in facilitating the biosynthesis of critical innate antiviral proteins is compelling for several reasons. Cells harboring +ssRNA virus infection face acute inhibition of host protein synthesis, e.g., due to activation of the dsRNA-dependent protein kinase (PKR) or engaging of RNase L (34). Under these conditions of sudden-onset duress and global protein synthesis repression, cells must retain translation capacity for biosynthesis of

![Figure 4](https://example.com/fig4)

**FIG 4** YTHDF3 depletion inhibits type I IFN-driven JAK/STAT1 signaling. (A) A375 or (B) HeLa cells were transfected with ctrl siRNA or one of two siRNAs targeting YTHDF3 48 h prior to treatment with 200 U/ml of IFN-α. (C) A375 cells were transfected with ctrl siRNA or siRNA targeting YTHDF3 48 h prior to treatment with 200 U/ml of IFN-γ and lysed at the indicated time point for immunoblot analysis. (D) A375 cells were transfected with ctrl siRNA or siRNA targeting YTHDF3 48 h prior to PVSRIPO infection (MOI 10; 24 h) in the presence or absence of Ruxolitinib (50 nM), and the relative induction of viral protein expression upon YTHDF3 depletion was quantified for the two conditions. (E) HeLa cells were transfected with ctrl siRNA or siRNA targeting YTHDF3 48 h prior to PVSRIPO infection (MOI 10; 4.5 h), with or without 4 h pretreatment with 100 U/ml of IFN-α, and the relative induction of viral protein expression upon YTHDF3 depletion was quantified for the two conditions (n = 5). Graphs represent mean ± SEM; *, **, and *** correspond to P < 0.05, P < 0.005, and P < 0.0005, respectively.
critical host response factors such as ISGs. Alternatively, YTHDF3 may promote degradation of negative regulators of JAK/STAT1 signaling. This model is bolstered by a study showing that METTL3-deficient T cells are deficient in JAK/STAT5 signaling due to aberrant induction of multiple members of the suppressor of cytokine (SOCS) family of proteins, which negatively regulate this pathway (33). However, our investigations did not indicate a role of YTHDF3 in regulating SOCS/USP18 abundance at the transcriptional or translational levels.

A recent report suggested that YTHDF1 inhibits antigen cross-presentation in antigen-presenting cells (APC) via regulation of cathepsin expression and antigen degradation (35). PVsRIPO is in experimental use as a cancer immunotherapy agent in glioblas
toma (36) and other indications. PVs naturally target APCs for infection (37), and PVsRIPO sublethal infection, lingering viral replication, and proinflammatory stimulation of tumor-associated APCs are implicated in instigating tumor antigen-specific antitumor immunity (38). Further studies must examine whether PVsRIPO 2Apro-mediated YTHDF cleavage occurs in this context in vivo, whether it can stimulate cross-presentation, and if it is involved in antitumor immunity elicited by PVsRIPO.

MATERIALS AND METHODS

Cell lines, in vitro transcription, and DNA/RNA transfections. HeLa R19 (39), SUM149 (40), A375, and T3M4 cells (both ATCC) were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and nonessential amino acids. siRNA transfections were performed 36 h prior to infection at ~50% confluence with 50 µM siRNA and 5 µl of Lipofectamine RNAiMax (Invitrogen) per well (6-well plate) in serum-free media. The sequences of siRNAs employed in this study are shown in Table S1 in the supplemental information. Myc-/Flag-tagged YTHDF3 was purchased from Origene. The Y90A/G91A mutations eliminating the 2Apro cleavage site were intro-
duced by QuickChange lightning site directed mutagenesis kit (Agilent) using primer pair 5’-ATGTTCTCCATATTACTATTTGTGCAGCGGTTGTCAGATATGGCATAGGC-3’/5’-GCTATGCCATATCTGGAGAAGATC-3’. These constructs were then transfected (6 h) with Lipofectamine 2000 (Invitrogen) into cells at 90% confluence according to the manufacturer’s protocol, 24 h prior to infection. WT and C109A 2Apro RNA constructs have been described previously (28). These constructs were in vitro transcribed using the mMESSAGE mMACHINE T7 transcription kit (Invitrogen). This capped RNA was then transfected (3 µg; 12 h) with DMRIE-C (Invitrogen) according to the manufacturer’s protocol.

Viral infections, inhibitors, cytokines, and one-step growth curves. PVsRIPO and CBV3 infections were performed at an MOI of 10 in DMEM supplemented with 1% FBS and nonessential amino acids (39, 41). Z-VDAMF-KK and Ruxolitinib (Tocris) were dissolved in DMSO and used at the indicated concentrations. IFN-γ and IFN-α2 (PBL) were used at the indicated concentrations. One-step growth curves and plaque assays were performed as reported before (39, 41).

Immunoprecipitation, immunoblotting, RT-qPCR, and LEGENDplex cytokine analysis. Lysate preparation, immunoprecipitation (IP), and immunoblotting have been described previously (42). For IPs, cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (Millipore) with halt protease-phos-
tatase inhibitor cocktail (Thermo Scientific). After overnight incubation with anti-Flag beads (Thermo Scientific), beads were washed 4 times in RIPA buffer and processed for immunoblotting. Total protein stains were performed using total protein stain (Li-COR). Quantifications for immunoblot were normalized to total protein. Blots were developed using Western Bright (BioExpress) or SuperSignal West Pico/ Femto (Thermo Scientific) chemiluminescence (ECL) kits. Antibodies against YTHDF1, YTHDF2, YTHDF3 (Proteintech), eIF4G1, G3BP1, PABP, GAPDH, p-STAT1(Y701), p-IRF3(S396), IRF3, STAT1, MDAS, IFIT1, ISG15 (Cell Signaling Technology), Flag (Invitrogen), poliovirus 2C (42), and CVB3 3D (a generous gift from K. Klingel, University of Tübingen) were used. For reverse transcriptase quantitative PCR (RT-qPCR), cells were lysed directly in TRIzol (Invitrogen) to isolate total RNA. The samples were treated with DNase (NEB) prior to cDNA synthesis (Invitrogen SuperScript III) following the manufacturer’s protocol. RT-qPCR was performed using SYBR green (Thermo) on a QuantStudio3 machine (Thermo). The sequences of primers used for RT-qPCR analyses in this study are shown in Table S1. For cytokine release assays, the LEGENDplex human antiviral kit was used as described before (29).

Statistical analysis. Quantification of immunoblot data was performed with the Li-COR Odyssey FC2 imaging system and Image Studio software. All experiments were repeated at least 3 times. Normalization methods for quantified immunoblot data are described in the figure legends and were represented as averages and standard errors of the means (SEM). The two-tailed Student’s t test was used for each comparison. Significance was defined as a P value of <0.05 and described in figure legends.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, TIF file, 0.1 MB.

FIG S2, TIF file, 2.7 MB.
FIG S3, TIF file, 0.5 MB.
FIG S4, TIF file, 0.5 MB.
FIG S5, TIF file, 1.2 MB.
TABLE S1, TIF file, 1.7 MB.

ACKNOWLEDGMENTS
This work was supported by PHS grants NS108773 (M.G.) and F32CA224593 (M.C.B.) and a grant from Hope & Gavin Wolfe.

J.P.K., M.C.B., and M.G. conceived and designed the study. J.T. assisted with initial cleavage characterization. M.W.T. performed qRT-PCR experiments. M.C.B. performed Legendplex cytokine analysis and provided crucial experimental advice. E.Y.D and M.I.D. initially characterized the innate immune phenotypes of A375 and T3M4 cell lines. J.P.K. performed all other experiments. J.P.K., M.C.B., M.W.T., J.T., E.Y.D., M.I.D., and M.G. contributed to the writing and editing of the manuscript and approved the manuscript.

M.G. is a cofounder of, equity holder in, scientific advisor to, and paid consultant of Istari Oncology, Inc. M.G. and M.C.B. are coinventors of intellectual property licensed to Istari Oncology, Inc.

REFERENCES
1. Zhao X, Yang Y, Sun BF, Shi Y, Yang X, Xiao W, Hao YJ, Ping XL, Chen YS, Wang WJ, Jin KK, Wang X, Huang CM, Fu Y, Ge XM, Song SH, Jeong HS, Yanagisawa H, Niu Y, Jia GF, Wu W, Tong WM, Okamoto A, He C, Rendtelow Danielsen JM, Wang XJ, Yang YG. 2014. FTO-dependent demethylation of N6-methyladenosine regulates m6A splicing and is required for adipogenesis. Cell Res 24:1403–1419. https://doi.org/10.1038/cr.2014.151.
2. Wang L, Wen M, Cao X. 2019. Nuclear hnRNP A2/B1 initiates and amplifies the innate immune response to DNA viruses. Science 365:eaav0758. https://doi.org/10.1126/science.aav0758.
3. Zheng Q, Hou J, Zhou Y, Li Z, Cao X. 2017. The RNA helicase DDX46 inhibits innate immunity by entrapping m6A-demethylated antiviral transcripts in the nucleus. Nat Immunol 18:1094–1103. https://doi.org/10.1038/nimi.2017.380.
4. Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, Fu Y, Parisien M, Dai Q, Jia G, Ren B, Pan T, He C. 2014. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature 505:117–120. https://doi.org/10.1038/nature13270.
5. Wang X, Zhao BS, Roundtree IA, Lu Z, Han D, Ma H, Weng X, Chen K, Shi H, He C. 2015. N6-methyladenosine modulates messenger RNA translation efficiency. Cell 161:1388–1399. https://doi.org/10.1016/j.cell.2015.05.014.
6. Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabbkin MA, Elemento O, Pestova TV, Qian SB, Jaffrey SR. 2015. S’ UTR m6A promotes cap-independent translation. Cell 163:999–1010. https://doi.org/10.1016/j.cell.2015.10.012.
7. Zhou J, Wan J, Gao X, Zhang X, Jaffrey SR, Qian SB. 2015. Dynamic m6A mRNA methylation directs translational control of heat shock response. Nature 526:591–594. https://doi.org/10.1038/nature15377.
8. Shi H, Wang X, Lu Z, Zhao BS, Ma H, Hsu PJ, Liu C, He C. 2017. YTHDF3 facilitates translation and decay of N6-(methyladenosine)-modified RNA. Cell Res 27:315–328. https://doi.org/10.1038/cr.2017.15.
9. Li A, Chen YS, Ping XL, Yang X, Xiao W, Yang Y, Sun HY, Zhu Q, Baiada P, Wang X, Bhattarai DP, Zhao YL, Sun BF, Yang YG. 2017. Cytoplasmic m6A affects translation. Cell 171:249–259. https://doi.org/10.1016/j.cell.2017.10.
10. Zhang Z, Theler D, Kaminska KH, Hiller M, de la Grange P, Pudimat R, Rafalska I, Heinrich B, Bujnicki JM, Allain FH, Stamm S. 2010. The YTH domain is a novel RNA binding domain. J Biol Chem 285:14701–14710. https://doi.org/10.1074/jbc.M110.104711.
11. Dominissini D, Moshtagh-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, Cesarakis K, Jacob-Hirsch A, Amariglio N, Kupiec M, Sorek R, Rechavi G. 2012. Topology of the human and mouse m6A RNA methylation revealed by m6A-seq. Nature 485:201–206. https://doi.org/10.1038/nature11112.
12. Gokhale NS, McIntyre ABR, McFadden MJ, Roder AE, Kennedy EM, Gandara JA, Hopcraft SE, Quicke KM, Vazquez C, Willer J, Iklayeva OR, Law BA, Holley CL, Garcia-Blanco MA, Evans MJ, Suthar MS, Bradrick SS, Mason CE, Horner SM. 2016. N6-methyladenosine in Flaviviridae viral RNA genomes regulates infection. Cell Host Microbe 20:654–665. https://doi.org/10.1016/j.chom.2016.09.015.
13. Hao H, Hao S, Chen H, Chen Z, Zhang Y, Wang J, Wang H, Zhang B, Qiu J, Deng F, Guan W. 2019. N6-methyladenosine modification and METTL3 modulate enterovirus 71 replication. Nucleic Acids Res 47:362–374. https://doi.org/10.1093/nar/gky1007.
14. Rubio RM, Depledge DP, Bianco C, Thompson L, Mohr I. 2018. RNA m6A modification enzymes shape innate responses to DNA by regulating interferon beta. Genes Dev 32:1472–1484. https://doi.org/10.1101/gad.319475.118.
15. Winkler R, Gillis E, Lasman L, Safra M, Geula S, Soysir C, Nachshon A, Tai-Schmiedel J, Friedman N, Le-Trilling VTK, Trilling M, Mandelboim M, Hanna JH, Schwartz S, Stern-Ginossar N. 2019. m6A modification controls the innate immune response to infection by targeting type I interferons. Nat Immunol 20:173–182. https://doi.org/10.1038/s41590-019-0275-z.
16. Agel VI, Gmyl AP. 2010. Viral security proteins: counteracting host defenses. Nat Rev Microbiol 8:867–878. https://doi.org/10.1038/nrmicro2452.
17. Toyoda H, Nicklin MJ, Murray MG, Anderson CW, Dunn JJ, Studier FW, Wimmer E. 1986. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45:761–770. https://doi.org/10.1016/0092-8674(86)90790-7.
18. Etchison D, Milburn SC, Edery I, Sonenberg N, Hershey JW. 1982. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. J Biol Chem 257:14806–14810. https://doi.org/10.1016/0021-9258(82)93352-0.
19. Gustin KE, Sarnow P. 2001. Effects of poliovirus infection on nucleo-cytoplasmic trafficking and nuclear pore complex composition. EMBO J 20:240–249. https://doi.org/10.1093/emboj/20.1.240.
20. Hellen CU, Lee OK, Wimmer E. 1992. Determinants of substrate recognition by poliovirus 2A proteinase. J Virol 66:3330–3338. https://doi.org/10.1128/VJ.66.6.3330-3338.1992.
21. Kennedy EM, Bogerd HP, Kornepati AV, Tang CY, Nowak BL, Marshall JB, Horner SM. 2020. Altered m6A modification controls flavivirus replication. Cell Host Microbe 27:555.e8. https://doi.org/10.1016/j.chom.2019.06.002.
22. Gokhale NS, McIntyre ABR, Mattocks MD, Holley CL, Lazear HM, Mason CE, Horner SM. 2020. Altered m6A modification of specific cellular transcripts affects Flaviviridae infection. Mol Cell 77:542–555.e8. https://doi.org/10.1016/j.molcel.2019.11.007.
23. Zhang Y, Wang X, Zhang X, Wang J, Ma Y, Zhang L, Cao X. 2019. RNA-binding protein YTHDF3 suppresses interferon-dependent antiviral responses by promoting FOXP3 translation. Proc Natl Acad Sci U S A 116:976–981. https://doi.org/10.1073/pnas.1812361116.
24. Dobrikova EY, Goetz C, Walters RW, Lawson SK, Peggins JO, Muszynski K, Ruppel S, Poole K, Giardina SL, Vela EM, Estep JE, Gromeier M. 2012. Attenuation of neurovirulence, biodistribution, and shedding of a
poliovirus-rhinovirus chimera after intrathalamic inoculation in Macaca fascicularis. J Virol 86:2725–2759. https://doi.org/10.1128/jvi.06427-11.

25. Gromeier M, Alexander L, Wimmer E. 2016. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc Natl Acad Sci U S A 93:2370–2375. https://doi.org/10.1073/pnas.93.62370.

26. White JP, Cardenas AM, Marissen WE, Lloyd RE. 2007. Inhibition of cytoplasmic mRNA stress granule formation by a viral proteinase. Cell Host Microbe 2:295–305. https://doi.org/10.1016/j.chom.2007.08.006.

27. Kuyumcu-Martinez NM, Van Eden ME, Younan P, Lloyd RE. 2004. Cleavage of poly(A)-binding protein by poliovirus 3C protease inhibits host cell translation: a novel mechanism for host translation shutoff. Mol Cell Biol 24:1779–1790. https://doi.org/10.1128/mcb.24.4.1779-1790.2004.

28. Dobrikova EY, Grisham RN, Kaiser C, Lin J, Gromeier M. 2006. Competitive translation efficiency at the picornavirus type 1 internal ribosome entry site facilitated by viral cis and trans factors. J Virol 80:3310–3321. https://doi.org/10.1128/JVI.80.7.3310-3321.2006.

29. Mosahbeh MM, Dobrikova EY, Brown MC, Yang Y, Cable J, Okada H, Nair SK, Bigner DD, Ashley DM, Gromeier M. 2020. Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun 11:524. https://doi.org/10.1038/s41467-019-13939-z.

30. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsuki K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101–105. https://doi.org/10.1038/nature04734.

31. Walton RW, Brown MC, Sacco MT, Gromeier M. 2018. Engineered oncolytic poliovirus PVSRIPO subverts MDAS-dependent innate immune responses in cancer cells. J Virol 92. https://doi.org/10.1128/JVI.00079-18.

32. Alexopoulos L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732–738. https://doi.org/10.1038/35099560.

33. Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, Balbis W, Gao Q, Kroehling L, Chen Y, Wang G, Broughton JP, Chen YG, Kluger Y, Simon MD, Chang HY, Yin Z, Flavell RA. 2017. m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SC5 pathway. Nature 548:336–342. https://doi.org/10.1038/nature23450.

34. Donovan J, Rath S, Kolet-Mandrikov D, Korennykh A. 2017. Rapid RNase L-driven arrest of protein synthesis in the dsRNA response without degradation of translation machinery. RNA 23:1660–1671. https://doi.org/10.1261/rna.062000.117.

35. Han D, Liu J, Chen C, Dong L, Liu Y, Chang R, Huang X, Liu Y, Wong J, Dougherty U, Bissonnette MB, Shen B, Weichselbaum RR, Xu MM, He C. 2019. Anti-tumour immunity controlled through mRNA m(6)A methylation and YTHDF1 in dendritic cells. Nature 566:270–274. https://doi.org/10.1038/s41586-019-0916-x.

36. Desjardins A, Gromeier M, Herndon JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, S JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. 2018. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 379:150–161. https://doi.org/10.1056/NEJMoa1716435.

37. Shen L, Chen CY, Huang D, Wang R, Zhang M, Qian L, Zhu Y, Zhang AZ, Yang E, Qaqish A, Chumakov K, Kouivaiskaia D, Vignuzzi M, Nathanson N, Macadam AJ, Andino R, Kew O, Xu J, Chen ZW. 2017. Pathogenic events in a nonhuman primate model of oral poliovirus infection leading to paralytic poliomyelitis. J Virol 91. https://doi.org/10.1128/JVI.02310-16.

38. Brown MC, Holl EK, Boczkwowski D, Dobrikova E, Mosahbeh M, Chandramohan V, Bigner DD, Gromeier M, Nair SK. 2017. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med 9:eaan4220. https://doi.org/10.1126/scitranslmed.aan4220.

39. Brown MC, Bryant JD, Dobrikova EY, Shveygert M, Bradrick SS, Chandramohan V, Bigner DD, Gromeier M. 2014. Induction of viral, 7-methylguanosine cap-independent translation and oncology by mitogen-activated protein kinase-interacting protein kinase-mediated effects on the serine/arginine-rich protein kinase. J Virol 88:13135–13148. https://doi.org/10.1128/JVI.01883-14.

40. Holl EK, Brown MC, Boczkwowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK. 2016. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget 7:79828–79841. https://doi.org/10.18632/oncotarget.12975.

41. Brown MC, Dobrikov MI, Gromeier M. 2014. Mitogen-activated protein kinase-interacting kinase regulates mTOR/AKT signaling and controls the serine/arginine-rich protein kinase-responsive type 1 internal ribosome entry site-mediated translation and viral oncology. J Virol 88:13149–13160. https://doi.org/10.1128/JVI.01884-14.

42. Dobrikov MI, Dobrikova EY, Gromeier M. 2018. Ribosomal RACK1:protein kinase C betaII modulates intramolecular interactions between unstructured regions of eukaryotic initiation factor 4E (eIF4E) that control eIF4E and eIF3 binding. Mol Cell Biol 38. https://doi.org/10.1128/MCB.00306-18.